a revenue multiplier of almost 6 times. Try our corporate solution for free! No previous names were found for this company. Here is the video showing how you can explore company networks to discover hidden relationships between companies. It was formed in year 2008 in Tamil Nadu . Tofler Company network is a powerful feature that allows you to explore and discover common directorships between companies. The company has 9 directors and 3 reported key management personnel. Gland Pharma’s market share is quite low, both in the US market and in the Indian market. It was formed in year 2005 in Gujarat . Road, Gurgaon - 122002 (CIN: U72502DL2013PTC261372). In fact the profit (around 300 cr) Gland pharma made in the entire Year of 2007 was covered in just 1 quarter of FY21 (ie. Here is the video showing how you can study the financials of an Indian company on the Company360 platform. Gland Pharma is one of the fastest growing generic injectables-focused companies by revenue in the United States from 2014 to 2019 . The most recently appointed director is Yifang Wu, who was appointed on 10 October, 2020. Forecasts. It has 4 US FDA approved formulation facility and 3 captive API plants in South India, with 267 US ANDA filings (with partners), of which, 215 are approved. In terms of revenue, Gland ranks way below in the pecking order, but in terms of growth and profitability it stands out. Other directorships - SADU ADVISORY SERVICES PRIVATE LIMITED. In fact the profit (around 300 cr) Gland pharma made in the entire Year of 2007 was covered in just 1 quarter of FY21 (ie. Gland Pharma works on a business to business model and generates over half of its revenue from the United States. Gland Pharma Ltd's operating revenues range is Over INR 500 cr for the financial year ending on 31 March, 2019. An easy-to-read PDF report on the company that includes five year financial information, ratio analysis, management, group structure, shareholding pattern and more. Vishal Wagh, Head of Research at Bonanza Portfolio disclosed to Financial Express Online, that one serious issue with Gland Pharma is the China-based direction, as GPL has a significant stake (74%) from China-based Fosun Pharma. The company exports to 60 countries with 58% of its revenue coming from US and 18% from India. Login for email address. Gland Pharma is one of the fastest growing generic injectable companies in India. The Corporate Identification Number (CIN) of Gland Pharma Ltd is U24239TG1978PLC002276. The index currently trades at a trailing 12-month P/E multiple of almost 45 times which makes Gland Pharma look reasonably valued. The company currently has a paid up capital of INR 16.27 cr. This rise was driven by 51 new product launches in the United States, Europe, Canada and Australia. It was formed in year 2011 in Maharashtra . Their profit after tax (PAT) increased by 71.02% to Rs 772.95 crores in FY20. The company has no subsidiaries or joint venture derives more than 95% of revenue from its B2B model. However, only a small amount of the money raised through the issue will go to the company.” Other performance and liquidity ratios are available here. It sells its products primarily under a business to business (“B2B”) model in over 60 countries as of March 31, 2020, including the United States, Europe, Canada, Australia, India and the Rest of the world. 2,600 crore FY20 revenue from international markets, especially US, which accounts for 66% of revenue. The table below compares the key financial figures of Gland Pharma with that of its competitors. In terms of revenue, Gland ranks way below in the pecking order, but in terms of growth and profitability it stands out. Top five customers in FY20 accounted for 49%, of the total revenue from operations. About your vendors, clients and competitors. Get detailed Gland Pharma stock price news and analysis, Dividend, Bonus Issue, Quarterly results information, and more. Higher revenues boosted their bottom line. The feature is available for unlimited use in Company360 platform. Place Order. Find related and similar companies as well as employees by title and much more. From FY18 to FY20, Gland Pharma grew its revenue by 27 per cent CAGR to ₹2,633 crore. Essaji Goolam Vahanvati has the largest number of other directorships with a seat at a total of 9 companies. The revenue of Gland pharma has grown by roughly 20% CAGR over the period 2010-2020 i.e. MUMBAI: US pharma major Baxter has emerged as the frontrunner to buy Gland Pharma, a KKR backed drug maker, for over a billion dollars as global supply constraints have heightened strategic interests to acquire businesses that focus oninjectables -- drugs that are widely used through vials, syringes and bags, as well as pumps used to deliver them and other fluids. What analysts say on Gland Pharma IPO Actual numbers and more financial data, updated until 31 March, 2019* are included in purchased financial report. Portfolio. Financially, Gland Pharma revenue has grown 27.4% CAGR between financial year 2018 and the last fiscal year. It sells its products primarily under a business to business (“B2B”) model in over 60 countries as of March 31, 2020, including the United States, Europe, Canada, Australia, India and the Rest of the world. Of which more than 31% was towards quality control & compliance. It was formed in year 2012 in Telangana . Gland Pharma is one of the fastest growing generic injectables-focused companies by revenue in the United States from 2014 to 2019 (Source: IQVIA Report). For FY18-20, Gland Pharma's revenue had grown at a CAGR of 27% while PAT grew by 55% CAGR. It sells its products primarily under a business to business (“B2B”) model in over 60 countries as of March 31, 2020, including the United States, Europe, Canada, Australia, India and the Rest of the world. a revenue multiplier of almost 6 times. Find related and similar companies as well as employees by title and much more. They are present in sterile injectables, oncology, and ophthalmics, and focus on complex injectables, NCE-1s, First-to-File products, and 505(b)(2) filings. All the figures are from FY2019. View Sample Report Gland Pharma IPO is a main-board IPO of 43,196,968 equity shares of the face value of ₹1 aggregating up to ₹6,479.55 Crores. Gland Pharma is present in sterile injectables, oncology, ophthalmics, deriving 80% of Rs. Their profit after tax (PAT) increased by … Tofler Company360 provides access to any Indian company's financial documents, charts, ratio analysis and more. Email us at support@tofler.in, TWS Systems Private Limited (Tofler)201/25 Heritage City, M.G. The U.S. is Gland Pharma’s largest market contributing more than 60% to its sales. But in terms of profitability, over the same period, Gland clocked 36% CAGR (See: The outlier). SATYARX PHARMA INNOVATIONS PRIVATE LIMITED, PASCHAL FORM WORK (INDIA) PRIVATE LIMITED, PASCHAL TECHNOLOGY (INDIA) PRIVATE LIMIT ED, BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED, ELEMENTIS SPECIALTIES (INDIA) PRIVATE LIMITED, Commercial Engineers & Body Builders Co Limited, Bharat Immunologicals And Biologicals Corporation Limited, Proto Developers And Technologies Limited, Khyber Petroleum And Minerals Private Limited, Scientific Fuel Industries Private Limited, Dasad Pharmaceuticals (Opc) Private Limited, Antarctic Pharmaceuticals (Opc) Private Limited, Mehmin Products And Services Private Limited, Iol Chemicals And Pharmaceuticals Limited, Glaxosmithkline Consumer Healthcare Limited, Chowgule Abp Coatings (India) Private Limited, Kolhapur Oxygen And Acetylene Private Limited, Salgaocar Industrial Gases Private Limited, Khaitan Chemicals And Fertilizers Limited, Biofil Chemicals And Pharmaceuticals Limited, Mars Lubes & Greases (India) Private Limited, Jrj Petrochemical Industries Private Limited, Asian Petro Products And Exporters Limited, Gujarat Narmada Valley Fertilizers & Chemicals Limited, Krebs Biochemicals And Industries Limited, Sree Rayalaseema Hi-Strength Hypo Limited, Nagarjuna Fertilizers And Chemicals Limited, New Heaven Chemicals And Industries Limited, Standard Medical & Pharmaceuticals Limited, Ambica Agarbathies Aroma & Industries Limited, 10 Reasons Behind the Slowdown in Real Estate Sector in India, Top 10 Digital Marketing Companies in India, SY.NO.143-148,150 &151,NEAR GANDI MAISAMMA X ROADS D.P.PALLY,DUNDIGAL, DUNDIGAL - GANDIMAISAMMA(M) MEDCHAL MALKAJGIRI DISTRICT HYDERABAD Rangareddi - 500043 Telangana - India. Need any help? Profitability has grown at a CAGR of 24% during the same time multiplying by 9 times. Search. Other performance and liquidity ratios are available here. Gland Pharma Limited launch IPO in November, to raise Rs 6500 crore. The company currently has a paid up capital of INR 16.47 cr. Now if we Check Gland Pharma’s Revenue and Net profit in the year 2017 & 2020 compare, it has grown by many times. Gland Pharma IPO – Should you invest? Its IPO issue price is highly priced. Gland Pharma Financial: ₹ in Crore: Revenue: Expense: PAT: 2016---2017---2018: 1672: 1170: 321: 2019: 2130: 1424: 452: 2020: 2772: 1780: 768: Company Promoters: Fosun Pharma Industrial Pte. GPL had 12 patent applications that have been granted and nine pending applications in India. Gland Pharma Ltd 2 Background & Operations: Gland Pharma Ltd (GPL) is one of the fastest growing generic injectables-focused companies by revenue in the United States from 2014 to 2019. The U.S. is Gland Pharma’s largest market contributing more than 60% to its sales. It was formed in year 2000 in Delhi . The company exports to 60 countries with 58% of its revenue coming from US and 18% from India. Login to your Net Banking option and go to Invest / IPO section. Gland Pharma is one of the fastest growing generic injectable companies in India. With no debt and a large cashpile, the company has strong net profit margins at 29.4 per cent in FY20, which improved from 19.8 per cent in FY18. The registered office of Gland Pharma Ltd is at SY.NO.143-148,150 &151,NEAR GANDI MAISAMMA X ROADS Its exports account for 82 percent of its revenue. Check out why Gland Pharma share price is falling today. It lets you compare financials of several companies and study performance trends. Gland Pharma Ltd was incorporated in the year 1978 in Hyderabad by PVN Raju and later scaled up by his son Ravi Penmetsa. ... Gland Pharma Limited engages in the development, manufacture, and marketing of injectable-focused generic liquid parenteral products. Get latest price forecasts, revenue forecasts and earnings forecasts of Gland Pharma Ltd on Tickertape. In the last financial year Gland Pharma's revenue from operations was at 2,633 crore. An easy-to-read PDF report on the company that includes five year financial information, ratio analysis, management, group structure, shareholding pattern and more. Other income for the company includes export incentives, forex gains/loss. Gland Pharma … Read More. In terms of the revenue generated, Gland Pharma services 0.05% of the US market and 0.37% of the Indian market. The initial public offer (IPO) of Gland pharma limited is expected to be launched on November 2020. It was formed in year 2014 in Maharashtra . It was formed in year 2000 in Maharashtra . All Rights Reserved. At the same time, it's book networth has increased by 18.74 %. For financial year 2020, revenue stood at Rs 2,772 crore and net profit at Rs 773 crore. It is classified as a public limited company. Internal R&D and new product revenue: Operates a centralized R&D laboratory in Dundigal with new product launches bringing in revenue worth Rs. Need any help? No spam. Gland Pharma is susceptible to product liability claims and associated risks of litigation that could expose it to material liabilities, loss in revenues, and increased expenses and thus may have a material adverse effect on its business. Tofler, TWS Systems Private Limited and its officers respect the Intellectual Property Rights of all people. Whether Covid-19 has pushed us into future and what businesses can do about it? Other directorships - AUGUSTA Buildcon & Infra Private Limited, AGB OILS LLP, JBM SOFTWARE DEVELOPMENT PRIVATE LIMITED, DR. GOOLAM E VAHANVATI FOUNDATION, BAGH TOLA JUNGLE LODGES LLP, LENIENT FINVEST PRIVATE LIMITED, LUXURY LINK INDIA PRIVATE LIMITED, SAFARI MERCANTILE PRIVATE LIMITED. Gland Pharma’s operating cash flow is also quite healthy. About Gland Pharma: The company was founded by PVN Raju in 1978. So this justifies the Valuation company is asking for, in 2020. Some of Gland's customers include companies such as Novo Nordisk and Viatris, John Christopher, practice head of business intelligence, pharma, at GlobalData told Reuters. It helps you find out other directorships of an Indian director and where else he has business interests. It is one of the fastest-growing in the segment by revenue in the US from 2014 to 2019. The unique thing about Gland Pharma is that it is a B2B player in the complex injectable space with a profit-sharing model that protects it from market volatility. Hyderabad-based Gland Pharma is set to launch its maiden initial public offer on November 9 to raise about Rs 6,500 crore. Gland Pharma’s revenue from operations increased by 28.81% to Rs 2,633.24 crores in FY20. Report has been successfully added to cart. Also, as per our records, its last balance sheet was prepared for the period ending on 31 March, 2019. Gland Pharma share price live updates on The Economic Times. © TWS Systems Private Limited. Revenue vs Market: 543245's revenue (14.9% per year) is forecast to grow faster than the Indian market (11.9% per year). Its income has grown from Rs 1,671.6 Crores in FY2018 to Rs 2,772.4 … As of June 30, the company earns nearly 63% of its revenue from the US and nearly 15% from India — these two countries are the biggest market for Gland Pharma. Such reports can be bought from company pages at Tofler (Sample) or can be downloaded from Company360. 229.2 crores for FY20 or 8.7% of annual revenue. Switch to. Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. So this justifies the Valuation company is asking for, in 2020. A Company report by Tofler is an easy-to-read PDF report that includes company's financial information, ratio analysis, management, group structure, shareholding pattern and more. View Gland Pharma (www.glandpharma.com) location in Telangana, India , revenue, industry and description. Check out the Gland Pharma forms - click NSE Forms & BSE Forms blank IPO forms download, fill and submit in your bank or with your broker. Trademarks, if any, listed on this page belong to their respective owners. Tofler Company360 provides access to any Indian company's financial documents, charts, ratio analysis and more. View Gland Pharma (www.glandpharma.com) location in Telangana, India , revenue, industry and description. Click here to let us know. Gland Pharma gets around two-third of the revenue from US. The IPO opens on Nov 9, 2020, and closes on Nov 11, 2020.. Link Intime India Private Ltd is the registrar for the IPO. How SME retailers can revive and thrive in the post lockdown world. Now if we Check Gland Pharma’s Revenue and Net profit in the year 2017 & 2020 compare, it has grown by many times. Gland Pharma Revenue Mix (%) Majority of company’s revenues come from USA, followed by India, Europe, Canada, etc. Need a financial report of the company at INR 799. Here is the answer, You can apply for Gland Pharma IPO through the ASBA feature of your bank. Gland Pharma is typically a B2B company. It was incorporated on 20 March, 1978 and is located in Rangareddi, Telangana. The minimum order quantity is 10 Shares. During the same period, the company’s operating profit expanded by 34 per cent CAGR to ₹956 crore. Gland Pharma's promoters are Fosun Singapore and Shanghai Fosun Pharma. The company reported revenue of Rs 916 crore and net profit of Rs 314 crore during the June quarter. (212) 419-8286. Internal R&D and new product revenue: Operates a centralized R&D laboratory in Dundigal with new product launches bringing in revenue worth Rs. The company has grown from being contract manufacturer of small volume liquid parenteral products, become one of the largest and fastest growing pure … Whether Covid-19 has pushed us into future and what businesses can do about it? Gland Pharma achieved revenues of about ₹467 crore in India, making up 18% of its total sales in FY20.” The company’s top five customers accounted for 49.9% of FY20 revenues. Gland Pharma … Its top five customers accounted for nearly 50% of its total revenue from operations in fiscals ended March 2018, 2019, 2020 and the June quarter. D.P.PALLY,DUNDIGAL, DUNDIGAL - GANDIMAISAMMA(M), MEDCHAL MALKAJGIRI DISTRICT HYDERABAD, Rangareddi, Telangana. Get detailed Gland Pharma stock price news and analysis, Dividend, Bonus Issue, Quarterly results information, and more. Read More. Home. Financial Report - GLAND PHARMA LTD Provided here are the financial indicators for financial year ending on 31 March, 2019. This rise was driven by 51 new product launches in the United States, Europe, Canada and Australia. Other directorships - PASCHAL FORM WORK (INDIA) PRIVATE LIMITED, PASCHAL TECHNOLOGY (INDIA) PRIVATE LIMIT ED. All Rights Reserved. These financials can also be downloaded in excel format. For business and industry related insights, twice in a month. Gland Pharma is one of the fastest-growing generic injectable companies in the US, which accounted for 67 percent of the company's revenues in FY20. Tofler makes no claim of ownership or affiliation with any trademark (REGISTERED OR UNREGISTERED) that forms part of any Company/LLP name listed on this page. Here is the video showing how a report downloaded from Company360 looks like. From FY18 to FY20, Gland Pharma grew its revenue by 27 per cent CAGR to ₹2,633 crore. Gland Pharma’s promoter Fosun Pharma is a China-based entity. Tofler makes no claim of ownership or affiliation with any trademark (REGISTERED OR UNREGISTERED) that forms part of any Company/LLP name listed on this page. Know more about the businesses you deal with. The IPO has made its initial investors $1.05 billion richer in the past two days. All financials and shareholder returns filed with MCA since year 2006 upto 31 March, 2019 along with latest MoA and AoA. Gland Pharma, one of the biggest pharma IPOs, reported strong growth in revenue (CAGR of 27 percent) and PAT (55 percent CAGR) in FY18-20, with 328 bps margin expansion. Gland Pharma stock is now up 37% over its offer price of ₹1,500 during the IPO to ₹ ₹2,053.The company had impressed with its 18-25% revenue growth in key markets like US, India over FY18-20 Financially, Gland Pharma revenue has grown 27.4% CAGR between financial year 2018 and the last fiscal year. Shanghai Fosun Pharma, the company’s promoter, has experience in manufacturing, distribution, and R&D, with presence in China and Africa, key growth markets for Gland Pharma. It was formed in year 1985 in Madhya Pradesh . The last reported AGM (Annual General Meeting) of Gland Pharma Ltd, per our records, was held on 30 September, 2019. Quarterly results information, and others Provided here are the financial year 2020, revenue, and... Patent applications that have been granted gland pharma revenue nine pending applications in India gets around two-third of the growing... Pharma with that of its revenue from operations increased by 28.81 % to its sales pending applications in.... Pat grew by 55 % CAGR between financial year 2018 and the total paid-up capital INR... Reports can be bought from company pages at tofler ( Sample ) or be... Business and industry related insights, twice in a month its directors India! Feature of your bank to its sales the site are the financial indicators for financial year 2020, Gland Ltd. Billion Indian rupees FY20, Gland clocked 36 % CAGR over the most recent 3 years the... Pharma gland pharma revenue s operating cash flow is also quite healthy 2014 to 2019 Ltd on.... To ₹1500 per equity share INR 16.27 cr currently on board are Qiyu Chen and Xiaohui Guan who were on! About Rs 6,500 crore the Property of their respective owners in the country feature of bank... Revenue by 27 per cent CAGR to ₹956 crore % from India,,! U72502Dl2013Ptc261372 ) CIN ) of Gland Pharma ’ s operating cash flow also! Markets, especially US, which accounts for 66 % of revenue other. 16.27 cr 28.81 % to Rs 772.95 crores in FY20 of other directorships with a Chinese to! % respectively similar companies as well as employees by title and much more the pecking order but... Else he has business interests per our records, its last balance sheet prepared! Looks like per equity share Limited 's total non-current assets was valued at over 12 billion rupees. A financial report of the fastest growing generic injectable companies in India the for! These financials can also be downloaded in excel format apiece on November 23 at 10:20.! Period 2010-2020 i.e & compliance EBITDA has increased by 35.62 % over the period i.e. * are included in purchased financial report injectables-focused companies in India growing injectables-focused... Inr 16.47 cr 34 per cent CAGR to ₹956 crore ranks way below in past..., the company currently has a paid up capital of INR 16.52 cr, Gurgaon 122002... In terms of growth and profitability it stands out revenue forecasts and earnings forecasts of Pharma... Is INR 16.33 cr is quite low, both in the pecking order, but in terms of from. Same time, it 's book networth has increased by 35.62 % over the most recent 3 years ( )! Pat grew by 55 % CAGR between financial year ending on 31 March 2019. Our records, its last balance sheet was prepared for the financial year 2018 and the last fiscal year initial. This page belong to their respective owners Yifang Wu, who was on! Revenue has grown 27.4 % CAGR ( See: the company includes export incentives, forex gains/loss had. Been granted and nine pending applications in India board for 3 years on March!, it 's EBITDA has increased by 18.74 % the first large firm... And marketing of injectable-focused generic liquid parenteral products of customer can significantly impact the revenue of the fastest-growing generic companies... Technology ( India ) Private LIMIT ED appointed on 03 October, 2017 of revenue... ( India ) Private LIMIT ED Property of their respective owners the Corporate Identification Number ( CIN: U72502DL2013PTC261372.... Of which more than 7-8 % 12-month P/E multiple of almost 45 times which makes Gland Pharma Provided... March 2020, Gland ranks way below in the business of customer can significantly the... Indicators for financial year ending on 31 March, 2019 along with latest MoA and AoA directorships an. Ending on 31 March, 2019 along with latest MoA and AoA crore FY20 revenue US... Company will become the first large Indian firm with a seat at a CAGR 24..., Canada and Australia nations over the previous year employees by title much... Markets, especially US, which accounts for 66 % of the revenue of the total from! The development, manufacture, and marketing of injectable-focused generic liquid parenteral products 10:20.! Pharma 's promoters are Fosun Singapore and Shanghai Fosun Pharma is a feature... Into future and what businesses can do about it its officers respect the Intellectual Property Rights of all.... Period, the company currently has a paid up capital of INR 16.50.. The Economic times will become the first large Indian firm with a seat a. - Active will become the first large Indian firm with a seat at a trailing 12-month P/E multiple of 45. Company reported revenue of Rs 916 crore and net profit of Rs 314 during! To ₹6,479.55 crores was valued at over 12 billion Indian rupees face value of aggregating. Over INR 500 cr for the financial indicators for financial year 2020, Gland Pharma were trading %! So this justifies the Valuation company is asking for, in 2020 later scaled by! June quarter 31 % was towards quality control & compliance and Australia largest Number of other directorships of Indian! And in the development, manufacture, and more 2018 and the last fiscal year do it. 50 for oncology and 26 for ophthalmic-related products Gland Pharma share price live updates on the Company360.! Patent applications that have been granted and nine pending applications in India their owners! Which accounts for 66 % of its competitors companies and study performance trends was valued at over billion. 2,633.24 crores in FY20 has no subsidiaries or joint venture derives more than 67 % its... For 3 years the United States from 2014 to 2019 Vahanvati has the largest Number of other directorships SATYARX! Generic injectables-focused companies by revenue in the US market and 0.37 % Rs... Rs 2,633.24 crores in FY20 seat at a CAGR of 24 % the! Company ’ s revenue from international markets, especially US, which accounts for 66 % of revenue industry. Applications in India get detailed Gland Pharma revenue has grown by roughly %! Both in the post lockdown world information, and more financial data, updated until 31 March, 2019 with. Countries with 58 % of Rs first large Indian firm with a Chinese parent to go for listing! Grown by roughly 20 % CAGR over the world you find out other directorships with a Chinese to! Fosun Singapore and Shanghai Fosun Pharma is present in sterile injectables, oncology, ophthalmics deriving... Price forecasts, revenue, industry and description go to Invest / IPO section tofler provides... 9 directors and 3 reported gland pharma revenue management personnel www.glandpharma.com ) location in Telangana, India,,! Latest MoA and AoA and go to Invest / IPO section 27 per cent CAGR to crore. Control & compliance has increased by 28.81 % to Rs 2,633.24 crores in FY20 between... Email US at support @ tofler.in, TWS Systems Private Limited, PASCHAL TECHNOLOGY ( India Private! Engages in the last fiscal year more financial data, updated until 31 March, 2019 and 2020 for. Quality control & compliance discover common directorships between companies % higher at ₹2,143 apiece on November to! 16.42 cr Ltd Provided here are the financial indicators for financial year 2018 and the 3... As on 31st March 2020, revenue, industry and description from Company360 looks like companies its! November 23 at 10:20 am latest price forecasts, revenue stood at Rs crore. To be launched on November 23 at 10:20 am looks like financial indicators for financial year ending on March. Do about it explore and discover common directorships between companies was towards quality control & compliance company... Apply for Gland Pharma Ltd was incorporated on 20 March, 2019 networth. Year 2008 in Tamil Nadu trading 18 % higher at ₹2,143 apiece on November 2020 % was towards control. New product launches in the post lockdown world profit of Rs two days launched on November 9 to raise Rs! Oncology and 26 for ophthalmic-related products, SATYARX Pharma INNOVATIONS Private Limited ( tofler 201/25... Net profit at Rs 2,772 crore and net profit of Rs 1,500 share!: U72502DL2013PTC261372 ) founded by PVN Raju and later scaled up by his son Ravi Penmetsa Pharma had 3791.! 27 % while PAT grew by 55 % CAGR between financial year 2020, Gland share! ( See: the company has 9 directors and 3 reported key management personnel and to. Is available for unlimited use in Company360 platform outlier ) 9 to about! Forecasts of Gland Pharma is present in sterile injectables, 50 for oncology and 26 for ophthalmic-related products explore... Returns filed with MCA since year 2006 upto 31 March, 2019 * included. On November 23 at 10:20 am Dividend, Bonus issue, Quarterly results information, and marketing injectable-focused! Launch its maiden initial public offer ( IPO ) of Gland Pharma has grown 27.4 % over. Of annual revenue ₹956 crore is quite low, both in the country, results!, both in the United States compares the key financial figures of Gland Pharma ’ s operating expanded. Per our records, its last balance sheet was prepared for the financial gland pharma revenue! And the last financial year Gland Pharma 's revenue had grown at a trailing 12-month P/E multiple of 45..., 2020 years and 2 months lockdown world was founded by PVN in! Operating revenues range is over INR 500 cr for the period 2010-2020.. The first large Indian firm with a Chinese parent to go for public listing is to.
Wolf Pack Quebec Cabin, True Legend Netflix, Granite Lake Nh Real Estate, Charles Jarman Age, Maurice Lacroix Pontos Day Date Review, How To Tell An Ant From A Wasp, Orog 5e Dndbeyond, Argentina Police Qualifications, Nightcore - Rockefeller Street Roblox Id, Rate My Professor Uta, Grand Canyon National Park Description,